Summary
Drugmakers worldwide face growing scrutiny over their research pipelines, as valuations increasingly depend on successful late-stage trials rather than blockbuster drugs nearing patent expiry.
AstraZeneca launches US$1.5bil annual savings plan to invest in drug pipeline
Source & full coverage: this summary is aggregated from Free Malaysia Today Business, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at Free Malaysia Today Business →
